Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions
Knee OsteoarthritisKnee Pain ChronicJoint DiseaseArthritisOsteo Arthritis KneeMusculoskeletal Disease
Interventions
PROCEDURE

HAM and HUMCWJ Injections

SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.

Trial Locations (1)

15220

Scott Medical Health Center, Pittsburgh

All Listed Sponsors
lead

Sport and Spine Rehab Clinical Research Foundation

OTHER

NCT03337243 - Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis | Biotech Hunter | Biotech Hunter